Kieran T. Gallahue

Interim President & Chief Executive Officer at Intersect ENT, Inc.

Kieran T. Gallahue

Kieran T. Gallahue

Interim President & Chief Executive Officer at Intersect ENT, Inc.

Overview
Career Highlights

Intersect ENT, Inc.
CareFusion Corporation
ResMed, Inc.

RelSci Relationships

3188

Number of Boards

8

Birthday

1964

Age

55

Number of Awards

1

Contact Data
Trying to get in touch with Kieran T. Gallahue? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Kieran T. Gallahue likely has professional access to. A relationship does not necessarily indicate a personal connection.

Professional at DSM Biomedical, Inc.

Relationship likelihood: Strong

Former Chairman & Chief Executive Officer at Edwards Lifesciences Corp.

Relationship likelihood: Strong

Professional at Orthofix International NV

Relationship likelihood: Strong

Founder at Auris Surgical Robotics, Inc.

Relationship likelihood: Strong

Founder, Chief Executive Officer & President at Adagio Medical, Inc.

Relationship likelihood: Strong

Professional at Orthofix International NV

Relationship likelihood: Strong

Managing Director & Director at SPR Therapeutics LLC

Relationship likelihood: Strong

Chairman, President & Chief Executive Officer at Verb Surgical, Inc.

Relationship likelihood: Strong

Chief Financial & Administrative Officer at Hulman & Company

Relationship likelihood: Strong

Vice President, Associate General Counsel & Secretary at Edwards Lifesciences Corp.

Relationship likelihood: Strong

Paths to Kieran T. Gallahue
Potential Connections via
Relationship Science
You
Kieran T. Gallahue
Interim President & Chief Executive Officer at Intersect ENT, Inc.
Education
Bachelor's Degree in Economics & Accounting

Rutgers, The State University of New Jersey, is a leading national research university and the state’s preeminent, comprehensive public institution of higher education. Rutgers is dedicated to teaching that meets the highest standards of excellence; to conducting research that breaks new ground; and to providing services, solutions, and clinical care that help individuals and the local, national, and global communities where they live. Founded in 1766, Rutgers teaches across the full educational spectrum: preschool to precollege; undergraduate to graduate; postdoctoral fellowships to residencies; and continuing education for professional and personal advancement.

MBA

Harvard Business School (HBS) is the graduate business school of Harvard University in Boston, Massachusetts, United States. The school offers a large full-time MBA program, doctoral programs, and many executive education programs. It owns Harvard Business School Publishing, which publishes business books, leadership articles, online management tools for corporate learning, case studies, and the monthly Harvard Business Review.

Memberships
Member
2002 - Current

YPO (Young Presidents’ Organization) connects people with successful young chief executives in a global network unlike any other. Founded in 1950 in New York City by a young president named Ray Hickok, the organization unites approximately 20,000 business leaders in more than 120 countries around a shared mission: Better Leaders Through Education and Idea Exchange. A great deal has changed since YPO’s founding but certain things have remained the same: the value of a peer network and trusted mentors, the importance of ongoing education, and the need for a “safe haven” where issues can be aired in an environment of confidentiality. Over the past six decades, YPO has maintained its core commitment to these ideals while embracing change with each successive generation of young business leaders.

Career History
Professional
2018 - Current

Corporate Overview Our Focus We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. In June 2012, the US Food and Drug Administration (FDA) approved our internally discovered drug, BELVIQ® (lorcaserin HCl). Click here for additional information. We are also seeking regulatory approval for BELVIQ in additional territories. Regulatory agencies outside of the US will independently review BELVIQ. In addition to BELVIQ, our internally discovered, oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; GPR119 agonists, intended for the treatment of type 2 diabetes; and nelotanserin, an inverse agonist of the serotonin 2A receptor, which we previously studied for the treatment of insomnia

Interim President & Chief Executive Officer
2015 - Current

Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.

Professional
2015 - Current

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Critical Care portfolio products hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA..

Boards & Committees
Member, Board of Directors
2018 - Current

Corporate Overview Our Focus We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. In June 2012, the US Food and Drug Administration (FDA) approved our internally discovered drug, BELVIQ® (lorcaserin HCl). Click here for additional information. We are also seeking regulatory approval for BELVIQ in additional territories. Regulatory agencies outside of the US will independently review BELVIQ. In addition to BELVIQ, our internally discovered, oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; GPR119 agonists, intended for the treatment of type 2 diabetes; and nelotanserin, an inverse agonist of the serotonin 2A receptor, which we previously studied for the treatment of insomnia

Member, Board of Directors
2015 - Current

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Critical Care portfolio products hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA..

Director
Current

Systems Oncology LLC engages in the development of cancer drug and therapies. It combines multi-scalar systems modeling with machine learning and big-data to uncover breakthrough insights into cancer biology and expose new therapeutic vulnerabilities. The company is headquartered in Scottsdale, AZ.

Director
2012 - 2015

REPRESENT MEDICAL DEVICE MANUFACTURER'S ON DOMESTIC & GLOBAL REGULATORY & LEGISLATIVE ISSUES.

Director
Prior

The Healthcare Leadership Council (HLC), a coalition of chief executives from all disciplines within American healthcare, is the exclusive forum for the nation’s healthcare leaders to jointly develop policies, plans, and programs to achieve their vision of a 21st century system that makes affordable, high-quality care accessible to all Americans.

Director
Tenure Unconfirmed

BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA.

Political Donations
$1,000
2014

Representative from California's 52nd Congressional District

$500
2013

Representative from California's 52nd Congressional District

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
Rank #213
2014
Chief Executive Magazine - Wealth Creators
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Kieran T. Gallahue. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Kieran T. Gallahue's profile does not indicate a business or promotional relationship of any kind between RelSci and Kieran T. Gallahue.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/kieran-t-gallahue-3244722
  • https://relationshipscience.com/person/kieran-t-gallahue-3244722